9 May 2017 - Richard Torbett from the Association of the British Pharmaceutical Industry pens a letter to the Financial Times.

Sir, As the representative of companies that research and develop cancer medicines we disagree with some of the assertions in the article “Cancer fund failure highlights the dilemma of pricing drugs” (May 2) and the study it is based on: specifically the characterisation of the Cancer Drugs Fund as a “tragedy for patients” and the conclusion that medicines in the UK are unaffordable.

Read Financial Times article